Biofarma
Group

Exzell Pharma has partnered with Biofarma Group to offer EsopH®, an innovative treatment for heartburn symptoms associated with gastroesophageal reflux disease (GERD). Biofarma Group is a global leader in developing, producing, and packaging food supplements, medical devices, probiotic-based drugs, and cosmetics exclusively for third parties. With a turnover of approximately €436 million and over 1,500 employees, Biofarma Group is a key player in the healthcare sector in Italy and across Europe. This collaboration enables Exzell Pharma to introduce EsopH® to the Canadian market, providing an effective solution for those seeking relief from heartburn and GERD symptoms.